Page 5 - Efficacy Study News Today

A woman being vaccinated in Ahmedabad. | Reuters/Amit Dave On Saturday, the pharmaceutical company Bharat Biotech officially announced the sale prices for its Covid-19 vaccine, Covaxin. State governments will have to pay Rs 600 per dose while private hospitals will have to pay Rs 1,200 per dose. These prices, fixed far above the corresponding rates announced by the Serum Institute of India for its vaccine, Covishield, has surprised observers for many reasons. The Serum Insti...

Moderna Reports Shortfall; Merkel Gets Astra Shot: Virus Update Bloomberg 52 mins ago Bloomberg News (Bloomberg) -- Moderna Inc. said it will deliver less Covid-19 vaccine than planned to the U.K., Canada and other countries this quarter due to a shortfall in doses in its European supply chain. China is planning to approve its first foreign vaccine before July, according to people familiar with the matter. German Chancellor Angela Merkel got her first shot of the AstraZeneca v...

Dr Maha Hussain at the recent virtual ASCO Meeting. Credit: ASCO Second look analysing prostate cancer study data reaps new rewards Two studies unveiled at last month’s virtual Genitourinary Cancers Symposium, organised by the American Society of Clinical Oncology, will have implications for both the treatment of prostate cancer and the provision of screening, Peter Doyle reports In men with non-metastatic castration-resistant prostate cancer (nmCRPC) and rapidly rising prostate specific ant...

Feb 24, 2021 Making TCAR available for select patients leads to 10% lower MACE rates Hospitals that adopted transcarotid artery revascularization (TCAR) as an option for carotid revascularization saw a 10% reduction in perioperative major adverse cardiovascular events (MACE) in patients with carotid artery stenosis, according to a registry-based study, although other quality-of-care initiatives may also have played a part. In a study of data from the Society of Vascular Surgery’s Vascular Qua...

Trial PROSPERs China’s fight against advancing prostate cancer New results from the PROSPER trial helped persuade the Chinese government to approve enzalutamide for adult patients diagnosed with advanced non-metastatic castration-resistant prostate cancer, Peter Doyle reports It might be coincidental. But eight months after a joint study by the Peking First University Hospital and National Urological Cancer Center of China in Beijing found a lack of effective therapies in the world’s most ...

Interim Analysis of Recardios Phase II Clinical Trial Published in European Heart Journal Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its positive results of the interim analysis of Recardios Phase II clinical trial in AMI were published in the latest release of the European Heart Journal. The current version of the journal relates to the presentation during the 2020 Congress of the European Society of Cardiology. News prov...